Inicio › Cáncer de pulmón de células no pequeñas › Minnesota › Duluth
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Duluth, MN
13 estudios para Cáncer de pulmón de células no pequeñas buscan participantes en centros de Duluth y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutandoFase 3
- Essentia Health Cancer Center, Duluth
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
ReclutandoFase 2
- Essentia Health Cancer Center, Duluth
- Essentia Health Saint Mary's Medical Center, Duluth
- Miller-Dwan Hospital, Duluth
- y 1 más
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutandoFase 3
- Essentia Health Cancer Center, Duluth
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
ReclutandoFase 1/2
- St. Luke'S /ID# 273344, Duluth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
ReclutandoFase 3
- Research Site, Duluth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
ReclutandoFase 3
- Clinical Study Sites, Duluth
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
ReclutandoFase 3
- Miller-Dwan Hospital, Duluth
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutandoFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Essentia Health Cancer Center, Duluth
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2/3
- Essentia Health Cancer Center, Duluth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutandoEstudio observacional
- Essentia Health Cancer Center, Duluth
- Saint Luke's Hospital of Duluth, Duluth
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Duluth
Ensayos de Cáncer de pulmón de células no pequeñas en otras ciudades
- Houston, TX145 estudios
- New York City, NY120 estudios
- Arlington, VA104 estudios
- Nashville, TN97 estudios
- Boston, MA90 estudios
- Los Angeles, CA87 estudios
- St. Louis, MO73 estudios
- Chicago, IL61 estudios
- Baltimore, MD60 estudios
- San Antonio, TX59 estudios
- Columbus, OH56 estudios
- Washington, DC55 estudios
Otros estudios en Duluth
- Cáncer de pulmón11 estudios
- Cáncer de próstata7 estudios
- Cáncer de seno7 estudios
- Cáncer de colon6 estudios
- Cáncer de vejiga6 estudios
- Leucemia mielógena aguda6 estudios
- Cáncer de endometrio5 estudios
- Cáncer de estómago5 estudios
- Cáncer de recto5 estudios
- Cáncer de esófago5 estudios
- Cáncer de laringe5 estudios
- Melanoma5 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.